RAPT Company Profile and Key Details

Q: Who are the executives of RAPT?

Ms. Jennifer NicholsonSenior Vice President of Regulatory Affairs & Quality AssuranceMs. Gwen R. CarscaddenChief HR OfficerDr. William HoChief Medical OfficerDr. David WustrowSenior Vice President of Drug Discovery & Preclinical Devel.Dr. Dirk G. Brockstedt Ph.D.Chief Scientific OfficerDr. Brian Russell Wong M.D., Ph.D.Chief Executive Officer, Pres & DirectorSteve Young Ph.D.Vice President of TechnologyDr. Paul KassnerSenior Vice President of Quantitative & Computational BiologyMr. Rodney K. B. YoungChief Financial Officer, Principal Accounting Officer & Sec.Mr. Michael ListgartenGen. Counsel

NASDAQ : RAPT

RAPT Therapeutics

$58.01

0.00000110

At Close 4:00 PM

Not Actively Trading

56.57

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

RAPT Therapeutics, Inc. (RAPT) stock surged 0.00%, trading at $58.01 on NASDAQ, up from the previous close of $58.01. The stock opened at $58.01, fluctuating between $58.01 and $58.01 in the recent session.

Stock Snapshot

58.005

Prev. Close

959.26M

Market Cap

58.005

Day Low

-4.974699828473414

P/E Ratio

-11.66

EPS (TTM)

-2.56

Cash Flow per Share

58.01

Open

16.54M

Number of Shares

58.005

Day High

50.59%

Free Float in %

3.83

Book Value

10.85M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 02, 2026	57.98	58.02	57.98	58.02	11.09M
Feb 27, 2026	57.94	57.99	57.94	57.98	899.08K
Feb 26, 2026	57.95	57.96	57.94	57.96	1.02M
Feb 25, 2026	57.94	57.96	57.92	57.96	2.37M
Feb 24, 2026	57.94	57.98	57.91	57.93	1.03M
Feb 23, 2026	57.90	57.98	57.89	57.93	1.17M
Feb 20, 2026	57.82	57.98	57.79	57.92	1.6M
Feb 19, 2026	57.80	57.88	57.78	57.80	1.17M
Feb 18, 2026	57.79	57.85	57.74	57.74	865.76K
Feb 17, 2026	57.75	57.86	57.72	57.84	1.27M
Feb 13, 2026	57.82	57.82	57.71	57.72	12.05M
Feb 12, 2026	57.74	57.82	57.73	57.82	6.58M
Feb 11, 2026	57.76	57.81	57.71	57.72	7.78M
Feb 10, 2026	57.78	57.80	57.69	57.74	9.89M
Feb 09, 2026	57.71	57.80	57.69	57.77	5.14M
Feb 06, 2026	57.70	57.80	57.64	57.69	3.58M
Feb 05, 2026	57.73	57.76	57.64	57.68	11.02M
Feb 04, 2026	57.73	57.86	57.61	57.78	6.03M
Feb 03, 2026	57.70	57.79	57.65	57.75	4.85M
Feb 02, 2026	57.71	57.77	57.64	57.68	2.95M

Contact Details

South San Francisco, CA 94080

United States

https://www.rapt.com 650 489 9000

About Company

RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical firm specializing in immunology. The company is dedicated to discovering, developing, and commercializing innovative oral small molecule therapies. These treatments are aimed at addressing critical unmet medical needs for patients battling oncology and inflammatory diseases. Its primary drug candidate for inflammation, RPT193, functions as a C-C motif chemokine receptor 4 (CCR4) antagonist. This compound works by selectively preventing type 2 T helper cells from migrating into inflamed tissues. In the oncology pipeline, FLX475 stands as the company's leading candidate, also an oral small molecule CCR4 antagonist. This therapy is currently undergoing Phase 1/2 clinical trials to evaluate its efficacy both as a standalone treatment and in combination with pembrolizumab for individuals with advanced cancer. RAPT Therapeutics is also engaged in the development of a hematopoietic progenitor kinase 1 (HPK1) inhibitor. Founded in 2015, the company initially operated as FLX Bio, Inc. before rebranding as RAPT Therapeutics, Inc. in May 2019. Its corporate headquarters are situated in South San Francisco, California.

Stock Peers

ARGX

26.03+2.97%

argenx SE$903.75 REGN

2.56+0.42%

Regeneron Pharmaceuticals, Inc.$612.50 UTHR

1.70998+0.32%

United Therapeutics Corporation$538.30 MDGL

7.13+1.41%

Madrigal Pharmaceuticals, Inc.$512.88 VRTX

15.16+3.36%

Vertex Pharmaceuticals Incorporated$466.79 KRYS

-4.63-1.33%

Krystal Biotech, Inc.$343.43 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

21.08+7.47%

Praxis Precision Medicines, Inc.$303.39 ALNY

8.32+2.99%

Alnylam Pharmaceuticals, Inc.$286.41 LGND

-12.71-4.62%

Ligand Pharmaceuticals Incorporated$262.17

Company Overview

The stock is currently trading near its 52-week high $5.67 and $58.02. With a market capitalization of about $959.26 million, RAPT Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.44). Key stats such as the average daily volume over the past year has been around 2.34 million shares, trading with heavier-than-usual volume. Headquartered in South San Francisco, CA, RAPT Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Brian Russell Wong, the company employs approximately 67 people and listed since October 31, 2019. RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical firm specializing in immunology.

Technical Performance

RAPT has shown sold momentum, gaining 67.35% over the past week and 96.22% over the past quarter, though year-to-date performance is up 69.97%. Short-term trend indicators are bearishly aligned (SMA20 0.3%, SMA50 24.18%, SMA200 131.18%). The stock’s 14-day RSI is 78.96 (overbought), while the ATR of 0.64 points to moderate volatility. The stock remains hovering near 52-week lows, trading -0.03% below its high and over 923.09% above its low.

Valuation Metrics

RAPT Therapeutics, Inc. trades at a P/E ratio of -14.81, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 10.29 reflecting a rich premium to book value. The P/FCF stands at -11.07, also above market averages. Compared to sector medians, RAPT Therapeutics, Inc. P/S is trading at a discount to the sector, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

RAPT Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $32.43. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

RAPT Therapeutics, Inc. generated EPS of -$11.07 over the past year. Five-year average earnings growth is -10.1%. Wall Street analysts project EPS growth of 46.1% annually over the next five years. The latest quarter delivered EPS of -$9.12. The next quarter is forecast at -$0.83. Next year's EPS is expected at -$12.22. Analyst sentiment is bullish. Analyst rating data shows there are 14 Strong Buy ratings, 5 Buy ratings, 7 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $72.00 to $9.00. The high target offers 24.12% upside. The low target suggests -84.49% downside. The mean target is $45.92. This offers -20.84% upside. RAPT Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended March 05, 2026, missed forecasts by 1008.24%. The prior quarter beat by -26.14%. Over the last six quarters, Apple has recorded several small beats. These include -16.07% in November 12, 2024.

Shareholding & Insider Activity

RAPT Therapeutics, Inc. has 16.54 million shares outstanding. The public float is 3.91 million shares, elevated short interest at 3.12% of float. This equals 427.11 thousand shares. The short ratio is 4.43 days. Institutional investors hold 110.88% of the float. Insiders own 0.28%. Column Group LLC holds 1.24 million shares, TCG IV GP, LLC has 42.19 thousand shares and COLUMN GROUP II, LP has 42.19 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, RAPT Therapeutics has not generated any revenue. Returns are negative, with ROA at -67.39% and ROE at -79.44%.
On valuation metrics, RAPT Therapeutics trades at a P/E of -14.81, P/S of 0.00 and P/B of 10.29. The current ratio is 12.04 and quick ratio is 12.04. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -3836.15 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -33.35.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, RAPT Therapeutics posted revenue of $0.00, down slightly from $1.53M in the prior quarter. Gross profit was - $3.55M (margin 0.00%). Operating income was - $127.06M (margin 0.0%). Net income was- $116.80M (EPS - $3.05).
The company ended the quarter with $158.86M in cash and short-term investments, a total debt of $6.91M, and net debt of - $40.57M. Total assets were $173.33M, with equity of $147.04M. Financials further reflected weakness, with operating cash flow of - $97.05M, free cash flow of - $98.17M, and capital expenditures of - $1.13M.

Price Forecast & Outlook

Our AI price prediction model suggests that RAPT Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 12.13%, with price expected at $65.06 by March 16, 2026, within a range of $56.61 to $73.74 3-Month Outlook: Projected rise of 97.88%, reaching $114.81 by May 29, 2026, with a range of $114.10 to $115.48. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by March 02, 2027, within a range of $0.00 to $0.00.

Key Takeaways

RAPT Therapeutics, Inc. (NASDAQ:RAPT) shares are up 69.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows RAPT Therapeutics, Inc. trading at a premium to the broader market with a P/E of -14.81. Analyst sentiment is cautious, with the majority of ratings in Market Perform territory and a mean price target of $41.86, suggesting -27.85% downside. Our AI forecast model points to short-term strength (12.13% over two weeks), a medium-term rise (97.88% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current RAPT Therapeutics, Inc. (RAPT) stock price?

RAPT Therapeutics, Inc. (NASDAQ: RAPT) stock price is $58.01 in the last trading session. During the trading session, RAPT stock reached the peak price of $58.01 while $58.01 was the lowest point it dropped to. The percentage change in RAPT stock occurred in the recent session was 0% while the dollar amount for the price change in RAPT stock was $0.00.

RAPT's industry and sector of operation?

The NASDAQ listed RAPT is part of Biotechnology industry that operates in the broader Healthcare sector. RAPT Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RAPT?

Ms. Jennifer Nicholson
Senior Vice President of Regulatory Affairs & Quality Assurance
Ms. Gwen R. Carscadden
Chief HR Officer
Dr. William Ho
Chief Medical Officer
Dr. David Wustrow
Senior Vice President of Drug Discovery & Preclinical Devel.
Dr. Dirk G. Brockstedt Ph.D.
Chief Scientific Officer
Dr. Brian Russell Wong M.D., Ph.D.
Chief Executive Officer, Pres & Director
Steve Young Ph.D.
Vice President of Technology
Dr. Paul Kassner
Senior Vice President of Quantitative & Computational Biology
Mr. Rodney K. B. Young
Chief Financial Officer, Principal Accounting Officer & Sec.
Mr. Michael Listgarten
Gen. Counsel

How RAPT did perform over past 52-week?

RAPT's closing price is 923.88% higher than its 52-week low of $5.67 where as its distance from 52-week high of $58.02 is -0.03%.

How many employees does RAPT have?

Number of RAPT employees currently stands at 67.

Link for RAPT official website?

Official Website of RAPT is: https://www.rapt.com

How do I contact RAPT?

RAPT could be contacted at phone 650 489 9000 and can also be accessed through its website. RAPT operates from 561 Eccles Avenue, South San Francisco, CA 94080, United States.

How many shares of RAPT are traded daily?

RAPT stock volume for the day was 10.85M shares. The average number of RAPT shares traded daily for last 3 months was 2.34M.

What is the market cap of RAPT currently?

The market value of RAPT currently stands at $959.26M with its latest stock price at $58.01 and 16.54M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	67
Beta	0.44
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

RAPT Company Profile and Key Details

RAPT Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Technical Performance

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Valuation Metrics

Price Forecast & Outlook

Key Takeaways